MedTrace Logo

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

NCT07333261 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-02-13

No results posted yet for this study

Summary

This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.

Conditions

Interventions

DRUG

BMS-986453

Will be given as a single dose administered by IV infusion.

Sponsors & Collaborators

Principal Investigators

  • Susan Bal, MD · The University of Alabama at Birmingham

  • Luciano A Costa, MD · The University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-09
Primary Completion
2031-12-31
Completion
2041-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07333261 on ClinicalTrials.gov